Meeder Asset Management’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Meeder Asset Management’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,035	Closed	-$714	–	1806
2018 Q2	$714	Buy	9,035 +5,382	+147%	+$1.6K	﹤0.01%	1531
2018 Q1	$1K	Buy	3,653 +670	+22%	+$1K	﹤0.01%	1531
2017 Q4	$5K	Sell	2,983 -1,107	-27%	-$1.91K	﹤0.01%	1344
2017 Q3	$6K	Buy	4,090 +2,928	+252%	+$4.16K	﹤0.01%	1244
2017 Q2	$2K	Buy	1,162 +604	+108%	+$1.35K	﹤0.01%	1476
2017 Q1	$2K	Sell	558 -639	-53%	-$3.02K	﹤0.01%	1463
2016 Q4	$6K	Buy	+1,197	New	+$20.7K	﹤0.01%	848

Other funds holding ANTH

VCM

Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return

Meeder Asset Management's ANTH Position: Q3 2018 in Review

Meeder Asset Management sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q3 2018, closing a stake of 9,035 shares — an estimated $714 sold.

Meeder Asset Management first reported a position in ANTH in Q4 2016 and held it in 7 quarters. The position peaked at $6K in Q3 2017. 1 fund tracked by Wall St. Rank holds ANTH as of Q3 2018.

Meeder Asset Management reported no remaining Anthera Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Meeder Asset Management sold 9,035 Anthera Pharmaceuticals, Inc. shares in Q3 2018, an estimated $714.
Meeder Asset Management first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2016 and held it in 7 quarters.
Meeder Asset Management's Anthera Pharmaceuticals, Inc. position peaked at $6K in Q3 2017.
1 fund tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2018.

Based on Meeder Asset Management's 13F filing for Q3 2018, filed 2 Nov 2018.